

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number
WO 2005/089769 A1

(51) International Patent Classification⁷: **A61K 31/5513**

(21) International Application Number:
PCT/GB2005/001018

(22) International Filing Date: 18 March 2005 (18.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0406282.4 19 March 2004 (19.03.2004) GB

(71) Applicant (for all designated States except US): **ARROW THERAPEUTICS LIMITED** [GB/GB]; Britannia House, 7 Trinity Street, London SE1 1DA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **POWELL, Kenneth** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **KELSEY, Richard** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **CARTER, Malcolm** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **ALBER, Dagmar** [DE/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **WILSON, Lara** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **HENDERSON, Elisa** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **CHAMBERS, Phil** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **TAYLOR, Debra** [GB/GB]; Arrow

Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **TYMS, Stan** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **DOWDELL, Verity** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB).

(74) Agent: **SRINIVASAN, Ravi, Chandran**; J.A. Kemp & CO, 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/089769 A1

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OR OF THE RSV FUSION PROTEIN

(57) Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.